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Brief Review
Adrenergic Receptors
Models for Regulation of Signal Transduction Processes
John R. Raymond, Mark Hnatowich, Robert J. Lefkowitz, and Marc G. Caron
Adrenergic receptors are prototypic models for the study of the relations between structure and
function of G protein-coupled receptors. Each receptor is encoded by a distinct gene. These
receptors are integral membrane proteins with several striking structural features. They consist
of a single subunit containing seven stretches of 20-28 hydrophobic amino acids that represent
potential membrane-spanning a-helixes. Many of these receptors share considerable amino acid
sequence homology, particularly in the transmembrane domains. All of these macromolecules
share other similarities that include one or more potential sites of extracellular N-linked
glycosylation near the amino terminus and several potential sites of regulatory phosphorylation
that are located intracellularly. By using a variety of techniques, it has been demonstrated that
various regions of the receptor molecules are critical for different receptor functions. The seven
transmembrane regions of the receptors appear to form a ligand-binding pocket Cysteine
residues in the extracellular domains may stabilize the ligand-binding pocket by participating in
disulnde bonds. The cytoplasmic domains contain regions capable of interacting with G proteins
and various kinases and are therefore important in such processes as signal transduction,
receptor-G protein coupling, receptor sequestration, and down-regulation. Finally, regions of
these macromolecules may undergo posttranslational modifications important in the regulation
of receptor function. Our understanding of these complex relations is constantly evolving and
much work remains to be done. Greater understanding of the basic mechanisms involved in G
protein-coupled, receptor-mediated signal transduction may provide leads into the nature of
certain pathophysiological states. (Hypertension 1990;15:119-131)
The endogenous catecholamines epinephrineand norepinephrine are thought to modulateblood pressure homeostasis through at least
four potential mechanisms. First, catecholamines
affect blood pressure through actions on the central
nervous system.1 Second, they influence blood pres-
sure by directly controlling cardiovascular tone.2-4
Third, they modulate renal sodium flux, primarily in
the proximal tubule.5"8 Fourth, catecholamines can
affect renin release and the renin-angiotensin-
aldosterone system.9 The catecholamines, as well as
various synthetic congeners, initiate these actions by
specifically interacting with membrane-bound recep-
tor macromolecules. The interaction of catechol-
amines with their receptors typically fulfills several
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criteria. Binding to the receptors is rapid, saturable,
stereoselective, reversible, and of high affinity. Fur-
thermore, occupancy of the receptor by the appro-
priate agonist leads to generation of intracellular
second messengers and culminates in a physiological
response. As with many other receptors, those for
catecholamines are linked to specific effector systems
through intermediary signal-transducing proteins.
These are termed guanine nucleotide regulatory pro-
teins, or "G proteins" because they bind and hydro-
lyze the guanine nucleotide guanosine triphosphate
(GTP).10
Catecholamine (adrenergic) receptors can be sub-
divided into several distinct categories, based on
pharmacological specificity and physiological actions.
These include the a r , a2, /3r, and ft-adrenergic
receptor subtypes. These subtypes may be subdivided
yet further into sub-subtypes such as a^ and a^,11
and alA and alB,12~14 and perhaps others.15"17 These
distinct categories of receptors differ not only in their
specificity for various ligands but also in their speci-
ficity for coupling to G proteins and thereby different
second messenger systems. For instance, agonist acti-
vation of either the f)r or ft-adrenergic receptor
subtype classically leads to the generation of cyclic
adenosine monophosphate (cAMP) by stimulating
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FIGURE 1. Schematic representation of cell
signal transduction pathways linked to adren-
ergic receptor subtypes. Epi, epinephrine; NE,
norepinephrine; PE, phenylephrine; Iso, iso-
proterenol; Praz, prazosin; IND, indanidine;
DHE, dihydroergocryptine; Phent, phentol-
amine; DAG, diacylgtycerol; IP3, inositol
trisphosphate; ER, endoplasmic reticulum;
cAMP, cyclic adenosine 3',5'-monophos-
phate; GTP, guanosine triphosphate; GDP,
guanosine diphosphate; Prop, propranolol;
PIP2, phosphatidylinositol 4,5-bisphosphate;
ATT, adenosine triphosphate; PI, phosphati-
dylinositol; PIP, phosphatidylinositol 4-
monophosphate. indicates that these two
receptor subtypes have also been demon-
strated to couple to PIP2 hydrolysis when
expressed in hamster pulmonary fibroblast
cells.18 **Indicates that these data are based
on single study of recombinant receptors
expressed in CHO cells.17 ^"Indicates that
a1B-adrenergic receptors are thought to couple
primarily to PIP2 hydrolysis, whereas au-
adrenergic receptors are thought to couple in
an unknown fashion to dihydropyridine-
sensitive Ca2+ channels (see References 12
and 13 for reviews).
the enzyme adenylyl cyclase; this pathway is medi-
ated by the G protein G5. Conversely, agonist activa-
tion of a2-adrenergic receptor leads primarily to
inhibition of adenylyl cyclase via a distinct G protein,
G ( n In contrast, a,-adrenergic receptor activation
leads to generation of the second messengers diacyl-
glycerol and inositol trisphosphate by stimulating the
enzyme phospholipase C18; this pathway is mediated
by a pertussis toxin-insensitive G protein termed Gp,
although this term is not universally accepted (Gx or
Gz may be more appropriate).
Agonist occupancy of G protein-coupled recep-
tors or generation of these various second messen-
gers can activate a cascade of events leading to, for
example, the activation of specific kinases and sub-
sequent phosphorylation of proteins19 (e.g., the
cAMP-dependent protein kinase protein kinase A
[PKA], the Ca2+ phospholipid-dependent protein
kinase protein kinase C [PKC]),20-21 release of intra-
cellular Ca2+ stores,22 activation of ion channels23-24
or pumps,8 release of arachidonic acid,25 and gene
transcription (see Figure 1). The diversity of receptor
subtypes and effector systems linked to the adrener-
gic receptors allows for a wide array of physiological
responses and a complex web of potential feedback
mechanisms. Moreover, recent data suggest that indi-
vidual receptor subtypes may be capable of coupling
to different G proteins18-26-27 further illustrating the
complexity of receptor-activated signaling networks
(discussed below).
Although receptors for many hormones, peptides,
neurotransmitters, light,28 and perhaps even odorant
molecules29 are coupled to G proteins, the adrener-
gic receptors are perhaps the most thoroughly char-
acterized. As such, the adrenergic receptor family
may serve as a model for the study of the superfamily
encompassing all G protein-coupled receptors.
Three of the four main subtypes (au a^ and ft) have
been purified to homogeneity and reconstituted into
phospholipid vesicles with G proteins.30 The genes or
complementary DNAs (cDNAs) of at least six sub-
types have been isolated, sequenced, and expressed
Raymond et al Adrenergic Receptor Models 121
TABLE 1. Characteristics of the Second Messenger Linkages of the Cloned Adrenergic Receptors
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Experiments were performed in various mammalian cell lines orXenopus oocytes transiently or stably expressing recombinant adrenergic
receptors.17'18'4*-49-35-57 cAMP, cyclic adenosine 3',5'-monophosphate; PIP2, phosphatidylinositol 4,5-bisphosphate; EC50, dose at which half
maximal effect occurs; PTx, pertussis toxin. Agonists used for the ftadrenergic receptors and a-adrenergic receptors were isoproterenol and
epinephrine, respectively.
in mammalian cell lines.16-1731-38 Finally, their func-
tional regulation has been extensively studied by
covalent modification,19-39-41 mutagenesis,42-47 and
chimeric receptor construction.48-49 In this review, we
will discuss the relations of adrenergic receptor struc-
ture to such diverse functions as ligand binding, G
protein activation, desensitization, posttranslational
modifications, and other regulatory phenomena.
Classification of Adrenergic Receptors
Adrenergic receptors were initially subdivided by
Ahlquistso into two major subtypes, a and /3, based on
their pharmacological characteristics. This model
was subsequently refined to include subtypes, au a^
ft, and ft, based on functional correlates and phar-
macological specificity.51-53 More recent proposals
subdivide the a2-adrenergic receptor into at least two
subtypes (A,B) based on pharmacological differences
in affinities for prazosin, oxymetazoline, idazoxan,
and SKF104078.11-15 Clearly, the cloned human a^w-
receptor (named for the location of its gene on
chromosome 10) corresponds to the pharmacologi-
cally defined platelet a^-adrenergic receptor.11-36
However, other a2-adrenergic receptors such as that
expressed in OK cells, the cloned human a^-
adrenergic receptors (named for the location of its
gene on chromosome 4), as well as "prejunctional"
a2-adrenergic receptors, which have a low affinity for
the compound SKF104078, do not fit into this classi-
fication scheme.11-1516 A similar heterogeneity of
ai-adrenergic receptors (A and B subtypes) has been
proposed based on criteria such as relative potencies
of a series of antagonists, differential sensitivity to the
agonist methoxamine or to the alkylating agent chlor-
ethylclonidine, and differential requirements for cal-
cium in the generation of second messengers12-13 (see
Figure 1).
Biochemically, adrenergic receptors couple to sev-
eral well-characterized signal transduction systems.
Both ft- and ft-adrenergic receptors stimulate adenyryl
cyclase, as does the recently cloned ft-adrenergic
receptor,17 whereas a2-adrenergic receptors have been
classically shown to inhibit adenyryl cyclase in tissues
where they are expressed.4 However, it is evident that
many of these so-called cyclase-inhibitory receptors can
also couple to a positive modulation of ion channels54
or phospholipase C.26-27 The a,-adrenergic receptor on
the other hand is coupled to phospholipase C; however,
there is evidence to suggest that aradrenergic receptor
can also couple to arachidonic acid metabolism, pre-
sumably via phospholipase A25 and to calcium channels
via an unknown mechanism.12-14 It is not known
whether these actions are mediated by multiple recep-
tor subtypes, or via a single subtype linked to different
effector systems, although it seems apparent that at
least two subtypes of aj-adrenergic receptors exist. The
characteristics of the second messenger systems of the
cloned adrenergic receptors are presented in Table 1.
As more receptor genes are cloned, expressed, and
reconstituted, the complex interactions between the
various components of signaling pathways linked to G
protein-coupled receptors will be elucidated.
It is now clear that many of the pharmacological
subtypes of adrenergic as well as other receptors are
encoded by separate genes (see Figure 2) and that
the pharmacological and biochemical diversity
observed in various tissues and organisms is typically
not due to posttranslational modification of the prod-
ucts of a single gene. With this emerging heteroge-
neity, it is likely that the future classification of
adrenergic and other G protein-coupled receptors
should be based on a combination of pharmacology,
specificity of coupling to G proteins or effector
systems, physiological effects, as well as the chromo-
some location of the receptor genes.
Structure of G Protein-Coupled Receptors
As depicted in Figure 3, G protein-coupled recep-
tors are integral membrane proteins with several
striking structural features. These receptors consist
of a single subunit containing seven stretches of
20-28 hydrophobic amino acids, which represent
potential membrane-spanning a-helixes. The adren-
ergic receptors share considerable amino acid
sequence identity, with the highest homology residing
within the membrane-spanning domains and, to a
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FIGURE 2. Amino acid sequence comparison of cloned adrenergic receptors. Residue 1 of each receptor is an extracellular amino
terminal methionine. Putative membrane spanning domains (seven for each receptor) are represented by bars. These membrane-
spanning domains were determined by hydrophobicity analyses as described by Kyte and Doolittle.58 aXitrAdrenergic receptor
(human platelet) encodes the a^-adrenergic receptor; ax:4-adrenergic receptor gene encodes an aradrenergic receptor subtype that
does not currently fit into an accepted classification scheme.
lesser degree, in the first two cytoplasmic loops. In
general, the putative third cytoplasmic loops and the
amino and carboxyl termini are the most divergent.
Other members of this family of molecules that share
sequence homology with the adrenergic receptors
include receptors for 5-hydroxytryptamine (5-
HT),59-61 dopamine,62 acetylcholine,63 and light
(opsins).28'64 Other receptors, such as those for sub-
stance K,65 the yeast a- and a-mating factors,6667 a
chemoattractant receptor from the slime mold Dicty-
ostelium discoideum,68 as well as the mas oncogene
product,69 also share the same structural motifs but
have little amino acid sequence homology with the
adrenergic receptors. All of these macromolecules
share other similarities that include one or more
potential sites of extracellular N-linked glycosylation
near the amino terminus, and several potential sites
of phosphorylation in cytoplasmic domains that may
be involved in the regulation of their function. The
amino acid sequences of the adrenergic receptors
cloned to date are presented in Figure 3.
The biological significance of the putative struc-
tural arrangement of these receptors is currently a
matter of considerable conjecture. In fact, the pro-
posed arrangement for most of these receptors has
been based solely on hydropathicity plots and on
analogy with bacteriorhodopsin.58 The scarcity of
most of the G protein-coupled receptors, which
typically constitute 0.001% or less of total membrane
protein, makes confirmation of these structural
motifs difficult. The opsins are notable exceptions
because they are the most abundant proteins in
specialized bacterial membranes70 and mammalian
rod outer segments, which permits large scale protein
purification schemes. Consequently, the presence of
a bundle of seven transmembrane helixes has been
clearly established by high resolution electron dif-
fraction for the bacteriorhodopsin of Halobacterium
halobium.11 A similar arrangement for vertebrate
opsins has been supported by numerous techniques.63
Many elements of this model have been confirmed for
the turkey "ft-adrenergic receptor"72 and hamster /V
adrenergic receptor44 using several approaches includ-
ing limited proteolysis. However, it is clear that a
number of strategies will be required to firmly establish
the generality of the proposed model for other G
protein-coupled receptors (e.g., antibodies recognizing
specific receptor domains, electron diffraction, or x-ray
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FIGURE 3. Schematic drawing of putative arrangement of
the hamster fradrenergic receptor within the cell mem-
brane. Each circle represents an amino acid. The amino
terminus and three loops (E-I, E-II, and E-III) are
oriented extracellularfy. Seven putative transmembrane a-
helixes are represented as M-I through M-VII. Carbaxyl
terminus and three loops (C-I, C-II, and C-III) have a
cytoplasmic orientation. Grey and black circles, respec-
tively, represent serine and threonine residues that are
potential sites of phosphorylation by f}-adrenergic receptor
kinase. This basic structural arrangement is likely to be
shared by all of the cloned G protein—coupled receptors
(see Figure 2).
COOH
crystallography). Analogy with the opsins has generated
the hypothesis that the seven membrane-spanning
helixes may form a ligand-binding pocket, perhaps
stabilized by disulfide bonds (discussed in the next
section). Considerable evidence derived from studies of
mutagenesis of the ft-adrenergic receptor suggests that
this arrangement may be critical for several receptor
functions, including ligand binding and induction of
conformational changes important for transducing
intracellular signals via G proteins (see below).
On simple examination of the primary structure of
the various G protein-coupled receptors character-
ized so far, certain structural motifs appear to be
associated with receptors that are coupled to a partic-
ular signal transduction system. Receptors that are
coupled to the inhibition of the enzyme adenylyl
cyclase such as the a^-adrenergic receptor (a^m) and
a2c4-adrenergic receptor,16-36 5-HTu,60 dopamine
D2,62 and muscarinic M2 and M3 acetylcholine
receptors63-73 share short carboxyl termini and long
third intracellular loops. Recent evidence obtained
with eukaryotic expression systems suggests that a^-
adrenergic receptor (a^o), a^-adrenergic receptor,18
5-HT^,27 and muscarinic M2 and M3 receptors26-74-75
are also capable of coupling weakly to phosphatidyl-
inositol hydrolysis.
The a]B-adrenergic receptor,38 5-HT2,61 5-HTlc,59
and substance K receptors65 primarily stimulate
phosphatidylinositol hydrolysis. These receptors have
relatively long carboxyl termini and short third intra-
cellular loops. The M, and M, muscarinic acetylcho-
line receptors seem to be an exception to this motif as
they have relatively long third intracellular loops.59-73-
76 As expected, the carboxyl termini of the Mj and M,
receptors are longer than those of the a^-adrenergic
receptors, or^-adrenergic receptors,16-36 D2,62 M2 and
M3,63-73 and 5-HT^60 receptors. However, they are
shorter than those of the aiB-adrenergic receptors,3*
substance K, 5-HT2,61 and 5-HTlc59 receptors.
A third structural motif is shared by receptors that
primarily stimulate adenylyl cyclase or cGMP phos-
phodiesterase, such as the mammalian ft -adrenergic
receptor, ft-adrenergic receptor, and ft-adrenergic
receptor, the turkey ^-adrenergic receptor, and the
visual opsins.17-33-33-37-64 All have long carboxyl ter-
mini that are relatively rich in serine and threonine
residues and may serve as substrates for kinases such
as the y3-adrenergic receptor kinase, rhodopsin
kinase, or related kinases. Taken together, these
findings suggest that general secondary or tertiary
conformational motifs of the G protein-coupled
receptors may impart specificity to their linkage with
second messenger systems. However, much more
work will be necessary to delineate these relations in
an unequivocal fashion. The known effector systems
linked to the cloned adrenergic receptors are pre-
sented in Table 1. In the next several sections, the
relation of specific regions of the adrenergic receptor
molecules to their function will be discussed.
Functions of the Extracellular Domains
The extracellular domains of the G protein-
coupled receptors consist of the three extracellular
loops (E-I, E-II, and E-III) that connect the hydro-
phobic membrane-spanning stretches of amino acids
and the glycosylated amino terminus44 (see Figures 3
and 4). The role of the N-linked sugars of the amino
termini of these proteins has not yet been estab-
lished. However, several lines of evidence suggest
that they are not involved in ligand binding.77-79
Deglycosylated )32-adrenergic receptor or /32-
adrenergic receptor translated without glycosylation
by addition of tunicamycin to cultured cells, bind
ligand normally.77-78 Moreover, a mutant /32-
adrenergic receptor with a deletion of 10 amino acids
from the amino terminus, including both potential
sites of N-linked glycosylation, is nonglycosylated and
binds ligand normally.79 Thus, the functional role of
the amino terminus and its sugar moieties is not
currently known.
With respect to the extracellular loops, it has been
suggested that cysteine residues within these
domains may stabilize the ligand-binding pocket via
disulfide linkages.40-41-79 Comparison of the deduced
amino acid sequences of various members of this
receptor family (Figures 2 and 4) reveals a number of
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FIGURE 4. Posttranslational modifications of the human fc-adrenergic receptor. Depicted are two sites of extracellular N-linked
gfycosylation (Asn*16), four cysteine residues that may participate in disulfide bonds (Cys"*'84'190-'9'), an intracellular cysteine
residue (Cys341) that may serve as a site of attachment for a palmitate membrane anchor, as well as multiple threonine and serine
residues located in C-III and the cytoplasmic carboxyl terminus, which are potential sites of phosphorylation by protein kinase A
(PKA), protein kinase C (PKC), or p-adrenergic receptor kinase (PARK).
highly conserved cysteine residues (Cys106-184' "d 341 of
the human ft-adrenergic receptor) that are potential
candidates for disulfide bond formation. The role of
cysteine residues of the ft-adrenergic receptor has
been systematically studied by site-directed mutagen-
esis. In an early study, ligand binding was drastically
altered by substituting valine residues for Cys106 and
Cys184, two highly conserved extracellular cysteines.79
These investigators hypothesized that Cys106 and Cys184
participate in a disulfide bond because alterations in
ligand-binding properties were not additive when
both residues were substituted. More recently, Dohl-
man et al41 studied the effects of substitution of valine
for the four extracellular cysteines (Cys106-184490-191) and
all four transmembrane cysteines (Cys77-116'125-285) of the
human ft-adrenergic receptor. Substitutions of any
of the extracellular cysteines lowered ligand binding
and altered binding specificity, whereas substitutions
at any of the transmembrane cysteines had little
effect. Fraser40 has presented similar findings using
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the mutagenesis approach. These results suggest
that the four extracellular cysteines (CyS»«U84,i»;i9ij
of the ^-adrenergic receptor may participate in
disulfide bonds that stabilize the binding pocket.
Studies with rhodopsin suggest that this relation
may apply to other members of the family of G
protein-coupled receptors. Similar systematic
examination of the role of the cysteine residues of
bovine rhodopsin yielded similar results.80 These
findings are also consistent with previous chemical
modification studies of rhodopsin.81-82
Transmembrane Domains are Important for
Ligand Binding
The transmembrane domains of the adrenergic
receptors consist of seven hydrophobic stretches of
20-28 amino acids. These are identified in Figure 2
as M-I through M-VII. The evidence suggesting that
these conserved regions contain determinants critical
for ligand binding has come from several experimen-
tal approaches. By covalently labeling the PJ-
adrenergic receptor with a radioactive photoaffinity
probe, followed by chemical and enzymatic digestion,
Dohlman et al44 showed that a point of covalent
attachment was to M-II of the hamster ^-adrenergic
receptor. This assignment was confirmed by direct
amino acid sequencing, although the actual cova-
lently labeled amino acid could not be identified.
Another study showed that a similar photoaffinity
probe incorporated into two tryptic fragments of the
avian /3-adrenergic receptor; one contained M-I
through M-IV, and the other M-VII.72 Using two
different photoaffinity probes, Matsui et al83 local-
ized the covalent attachment site to the M-IV of the
platelet a2-adrenergic receptor. Evidence derived
from the study of muscarinic acetylcholine receptors
also suggests that the transmembrane domains may
be critical for ligand binding. It has recently been
deduced that the alkylating agent [3H]PrBCM labels
aspartate residues in M-II or M-III of the porcine
brain muscarinic receptors.81 These data fit the
model proposed for rhodopsin in which the chro-
mophore retinal is covalently attached to Lys296,
which resides within M-VII.85-86
Using site-directed mutagenesis techniques to
explore the role of the transmembrane regions of the
ft-adrenergic receptor in ligand binding, Dixon and
coworkers79-87 prepared a series of mutant hamster
ft-adrenergic receptors in which various regions of
the molecule were deleted. When expressed in COS-
7 cells, mutant ft-adrenergic receptors with deletions
of hydrophilic cytoplasmic or extracellular loops
showed virtually no alterations in their ligand binding
properties. However, deletions within the hydropho-
bic regions of the molecule ablated ligand binding.87
Similarly, Kobilka et al55 found that truncation of the
carboxyl terminus of the human /^-adrenergic recep-
tor midway through M-VII destroyed ligand binding.
Subsequently, it was shown that ligand-binding prop-
erties of the ^-adrenergic receptor could be drasti-
cally altered by substituting single, highly conserved
amino acid residues in M-I, M-II, M-III, or M-
Vii.45,88,89 These data strongly support the notion
that determinants for agonist and antagonist binding
lie within the transmembrane regions.
A third series of experiments using receptor chi-
merae has further underscored the importance of the
transmembrane regions of the adrenergic receptor in
determining ligand-binding properties. By using a
series of human /^-ft-adrenergic receptor'8 and a-f-
ft-adrenergic receptor49 chimerae, M-VI and M-VII
were shown to be most important in conferring
antagonist binding specificity. Although the determi-
nants for agonist binding overlapped with those for
antagonist binding, they were less distinct and clearly
not identical. These results are not surprising in view
of the proposed G protein-coupled receptor struc-
tural model. If M-I through M-VII form a ligand-
binding pocket, the amphipathic a-helical arrange-
ment could allow hydrophobic residues to be
oriented toward the membrane lipids, while certain
critically charged amino acids can be oriented toward
the aqueous inner surface to form a binding pocket.
Such a geometry would create many distinct potential
sites for interaction with agonists and antagonists.
Thus, each ligand might be positioned in the binding
pocket in a slightly different manner. Pharmacologi-
cal studies of various receptors further support this
notion. For example, the human ft-adrenergic recep-
tor has a low affinity for 5-HT, and the human 5-HTu
receptor has a low affinity for catecholamines. How-
ever, both receptors share high-to-moderate affinities
for certain antagonists such as cyanopindolol and
propranolol.60-90 These two receptors share =75%
sequence identity within M-VI and M-VII. Another
comparison can be made between the human 5-HTu
receptor60 and a rat brain dopamine D2 receptor.62
Each receptor exhibits a low affinity for the other's
endogenous agonist, but share high affinities (=1-50
nM) for compounds such as lysergic acid diethyl-
amide, lisuride, (+) butaclamol, spiroxatrine, meter-
goline, and buspirone.91 These receptors share
=50% sequence identity within M-II, M-III, M-VI,
and M-VII. Clearly, there is a complex relation
between the amino acid composition of the trans-
membrane regions and ligand-binding properties of
the G protein-coupled receptors.
Cytoplasmic Domains are Important for
Receptor-G Protein Interactions
The cytoplasmic domains of the G protein-
coupled receptors comprise the three intracellular
loops (C-I, C-II, and C-III) and the carboxyl terminus
(see Figures 2-4). These regions may be critical for
many receptor functions such as G protein coupling,
phosphorylation reactions, and desensitization. We
will discuss the functions of each of the cytoplasmic
domains separately, but their functions may overlap
considerably. In this regard, two regions, C-III and
the amino terminal portion of the carboxyl terminus,
are the best characterized. It has been firmly estab-
lished that C-III contains sequences important for
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receptor-G protein coupling. Initially, mutant ham-
ster /32-adrenergic receptors, which lacked C-III,
were shown to have greatly diminished ability to
stimulate adenylyl cyclase, suggesting that this region
of the receptor was important in G protein
coupling.42-87 The carboxyl end of C-III has been
shown to be particularly important. The N-terminal
region of C-III may also participate in G protein
coupling but in a more general fashion4247; however,
evidence to date indicates that this region may not
contain the major determinant of specificity for the
interaction of receptor with G proteins.49 Using
a^ft-adrenergic receptor chimerae, Kobilka et al49
demonstrated that a2-adrenergic receptor, into which
80 or 122 amino acids of the ft-adrenergic receptor
sequence had been inserted, could mediate stimula-
tion of adenylyl cyclase, albeit to a lesser degree than
wild-type /32-adrenergic receptor. These a2-#2-
adrenergic receptor chimerae contained the entire
C-III segment, 21 amino acids from the M-VI seg-
ment, and either the entire M-V and E-II or 7 amino
acids from M-V of the human ft-adrenergic receptor.
The former chimera mediated stimulation of adenylyl
cyclase more efficiently than the latter suggesting that
portions of M-V influence G protein coupling. This
influence is either due to a direct participation in
receptor-G protein coupling or to secondary effects
on conformation. Similar results have been obtained
with a mutant rhodopsin, where substitution of Lys248
at the carboxyl end of rhodopsin C-III greatly
decreased the ability of the molecule to couple to
transducin, the G protein primarily coupled to
opsins.92 In a similar fashion, the analogous vicinal
basic amino acid residues at the carboxyl end of C-III
(i.e., His269 and Lys270) of the human /^-adrenergic
receptor may play a critical role in receptor coupling
to G proteins (M. Hnatowich, B.F. O'Dowd, M.G.
Caron, R.J. Lefkowitz, unpublished observations).
Another cytoplasmic region thought to be impor-
tant for receptor-G protein coupling is the N-
terminal region of the carboxyl termini of both the
ft-adrenergic receptor42 and rhodopsin.93 A cysteine
residue (Cys341 of the /^-adrenergic receptor) con-
served in most G protein-coupled receptors charac-
terized so far may be of particular importance (see
Figure 4). O'Dowd et al39 have recently demon-
strated that Cys341 of the human ft-adrenergic recep-
tor is palmitoylated, and that substitution of this
residue results in a nonpalmitoylated form of the
receptor. This mutant demonstrates a marked reduc-
tion in receptor-mediated stimulation of adenylyl
cyclase. In the case of rhodopsin the analogous
cysteine residues in this region (Cys322, Cys323) have
been suggested to form a disulfide bridge92 or to
undergo fatty acylation with palmitic acid.93 It has
been speculated that palmitoylation of both rhodop-
sin and ft-adrenergic receptor may anchor this
region of the molecule to the plasma membrane in
such a way as to present a favorable conformation for
G protein coupling, thus essentially forming a fourth
intracellular loop (Figure 4).
The functions of other cytoplasmic domains are
less well characterized. Mutations of C-I of the
/^-adrenergic receptor result in very poor receptor
expression in transient expression systems, possibly
due to defective protein folding during assembly,
defective membrane insertion, or both.42-47.5579
Mutations of the carboxyl end of C-II appear not to
affect receptor function, whereas the integrity of the
amino portion of C-II, particularly the highly con-
served proline (Pro138 of human /^-adrenergic recep-
tor), may be essential for receptor-G protein
coupling.4247 Pro138 may either interact directly with
the G protein or contribute to coupling efficiency
through an indirect mechanism, such as conferring
the proper alignment of C-II with respect to other
regions of the receptor, which more directly interact
with the G protein. Direct evidence, however, will
have to await further studies.
The cytoplasmic domains of the ft-adrenergic
receptor may also be involved in various events that
lead to receptor desensitization:46'47 This aspect of
receptor function will be discussed in the next section.
Functional Regulation of Adrenergic Receptors
The functions of G protein-coupled receptors are
subject to dynamic regulation by a number of mech-
anisms. Covalent modification of the receptor (i.e.,
phosphorylation by various kinases) has been impli-
cated in the regulation of /3-adrenergic receptor
function.19 Phosphorylation of ^adrenergic receptor
is closely associated with impaired receptor
function,96-98 correlating with a decreased ability to
couple to its G protein G,. The paradigm in which
receptor phosphorylation reactions have been exam-
ined is the phenomenon known as desensitization.
Desensitization refers to the attenuation of respon-
siveness to a drug or hormone in its continued
presence. This phenomenon can markedly diminish
the therapeutic efficacy and duration of action of a
drug. In the realm of hypertension, the rapid tachy-
phylaxis associated with the use of the potent antihy-
pertensive trimethephan camsylate may be a clini-
cally important example of this phenomenon.
Several distinct patterns of phosphorylation of
adrenergic receptors have been correlated with dif-
ferent aspects of receptor desensitization. These
patterns differ with respect to their temporal occur-
rence as well as to their dependence on various
kinases or agonist occupancy. Two types of phosphor-
ylation reactions dependent on the presence of ago-
nists can lead to the two classical types of desensiti-
zation (heterologous and homologous). Homologous
desensitization refers to an attenuation of respon-
siveness to a single type of agonist after exposure of
the receptor to that particular agent. Heterologous
desensitization differs in that exposure of a cell to a
particular agonist brings about attenuation of
responsiveness to multiple agonists operating
through distinct receptors. In many systems, hetero-
logous desensitization can occur concomitantly with
homologous desensitization.
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The best characterized example of heterologous
desensitization in vivo is a feedback regulation of
/J-adrenergic receptors associated with phosphoryla-
tion by PKA.99-100 Thus, when adenylyl cyclase is
stimulated by any number of hormones, intracellular
levels of cAMP rise, PKA is activated, and receptors
are phosphorylated and desensitized. In vitro, the
rate, but not the extent, of phosphorylation of /3-
adrenergic receptor by PKA is increased by receptor
occupancy.98 Functional impairment of components
of the signal transduction network other than the
receptor may also participate in heterologous desen-
sitization. Several groups have explored the role of G
protein modification in heterologous desensitization.
Kassis and Fishman101 demonstrated that G, derived
from fibroblasts that exhibited heterologous desensi-
tization after exposure to prostaglandin E! was func-
tionally impaired when reconstituted into cyc~ S49
lymphoma cell membranes, but this situation may not
pertain to every system examined (reviewed in Ref-
erence 102). Evidence has also suggested that the
inhibitory G protein G, may participate in heterolo-
gous desensitization.103'104 Recent data suggest that
PKA or PKC can phosphorylate the catalytic subunit
of adenylyl cyclase in broken cell membrane
preparations105 and in whole cells in culture106 lead-
ing to an impairment105 or enhancement105'107 of
adenylyl cyclase activity. However, the physiological
relevance of these phosphorylation reactions is not
presently known.
Homologous desensitization should by definition
be simpler mechanistically as it is hormone specific.
Nonetheless, several distinct processes also appear to
contribute to this form of desensitization: 1) recep-
tors are rapidly uncoupled from the effector systems,
2) receptors are rapidly sequestered or internalized,
and 3) receptors are slowly down-regulated. The
exact mechanisms by which these processes mediate
homologous desensitization are not totally under-
stood. Current evidence indicates that the rapid
onset of desensitization involves the phosphorylation
of the ft-adrenergic receptor by a specific kinase. A
protein kinase, y9-adrenergic receptor kinase
(/3ARK) capable of phosphorylation of the ft,-
adrenergic receptor in the presence of agonist has
been identified and characterized.97-108"111 This
kinase phosphorylates the agonist-occupied form of
the ft-adrenergic receptor on serine and threonine
residues in the carboxyl terminus of the receptor.46-108
Phosphorylation of the receptor by /3ARK clearly
decreases ft-adrenergic receptor function, although
one or more proteins or other cofactors may be
necessary to fully express this effect.111 The effects of
/3ARK on the ft-adrenergic receptor are remarkably
analogous to those of the retinal enzyme rhodopsin
kinase, which phosphorylates rhodopsin in a light-
dependent fashion.112 Rhodopsin kinase phosphory-
lates multiple threonine and serine residues in the
carboxyl terminus and at least one threonine in the
third intracellular loop of rhodopsin. This process is
associated with a decreased ability of rhodopsin to
couple to transducin, its G protein. This process is
dependent on subsequent binding to arrestin (48 kDa
protein) to the phosphorylated rhodopsin.112 The
prospect that an analogous 48 kDa-like protein may
exist that participates with /3ARK in the regulation of
the ft-adrenergic receptor was suggested in a recent
study.111
Regarding the specificity of /3ARK, Benovic et
al113 have demonstrated that the human platelet
a^-adrenergic receptor is an excellent substrate for
/3ARK in an in vitro reconstitution system. The
phosphorylation of the a^-adrenergic receptor is
entirely agonist dependent. Although the physiolog-
ical relevance of this interaction is currently not
known, the potential interaction of £ARK with
receptors other than ft-adrenergic receptor raises an
intriguing question. How can /3ARK mediate
"agonist-specific" homologous desensitization when
it potentially phosphorylates many distinct recep-
tors? A clue lies in the agonist-dependent nature of
£ARK-mediated receptor phosphorylation. In this
sense, agonist occupancy of receptors can confer a
specificity of sorts. Agonist binding presumably
induces a conformational change in the receptor,
exposing previously unavailable /3ARK substrate
sites on the cytoplasmic domains of the receptor. The
recent cloning of the gene for ySARK114 should allow
this question to be specifically addressed.
Recent experiments using site-directed mutagene-
sis of the /E^-adrenergic receptor gene have delin-
eated the regions of the receptor involved in the
regulatory phosphorylation. These experiments have
also established a role for receptor phosphorylation
in the process of rapid desensitization. There are two
consensus sequences for phosphorylation of the
receptor by PKA, one in the third cytoplasmic loop
and another in the amino terminal part of the
carboxyl tail. In contrast, the putative sites of /3ARK-
induced phosphorylation appear to reside primarily
in a serine- and threonine-rich region toward the
distal part of the carboxyl terminal of the receptor.
When either of the PKA consensus sequences or the
presumed /3ARK phosphorylation sites of the recep-
tor are altered by site-directed mutagenesis, a
marked decrease in the ability of agonists to mediate
receptor phosphorylation is observed. This is corrob-
orated by a marked slowing and attenuation of the
desensitization process.46-56 These effects can be
demonstrated by examining whole cell cAMP or
hormone-stimulated adenylyl cyclase in mem-
branes.56-57 These observations delineate the sites of
covalent modification of the receptor by these
kinases and implicate these mechanisms in the pro-
cess of desensitization.
To date, virtually nothing is known of the struc-
tural regions of the receptors that are involved in
mediating receptor sequestration. Although it has
been contended by Cheung et al115 that those regions
of the third cytoplasmic loop of the ft-adrenergic
receptor that are involved in mediating coupling to G
proteins (see above) are also involved in mediating
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receptor sequestration, recent studies in our labora-
tory do not support this contention. Thus, a variety of
receptor mutants that are not capable of coupling to
G, are nonetheless able to be sequestered normally
(P. Campbell, M. Hnatowich, W.P. Hausdorff, M.
Bouvier, B.F. O'Dowd, M.G. Caron, RJ. Lefkowitz,
unpublished observations).
The structural basis for receptor down-regulation
is poorly understood but is a subject of current
investigation. There appears to be both cAMP-
dependent and cAMP-independent mechanisms that
lead to down-regulation. The mechanisms are likely
to be complex and involve alterations in the rates of
receptor degradation or assembly or processing, mes-
senger RNA (mRNA) stability, and alterations in the
rates of receptor gene transcription. In this connec-
tion, receptor mutants that cannot be phosphorylated
by PKA showed a slowed rate of cAMP-induced
receptor down-regulation.116'117 The attenuated rate
of receptor down-regulation is likely due to an alter-
ation in the rates of receptor degradation. Addition-
ally, it has recently been shown that cAMP stimulates
transcription of the /^-adrenergic receptor gene and
increases the steady-state levels of ^-adrenergic
receptor mRNA in DDT-1 MF2 cells."8 Clearly,
much more work will be necessary to unravel the very
complex mechanisms that control receptor down-
regulation.
G protein-coupled receptors are involved in the
responsiveness of numerous tissues and cells to a
variety of stimuli. Adrenergic receptors have served
as models for the study of the relations between
structure and function of G protein-coupled recep-
tors. The cloning of the genes or cDNAs for the
various subtypes of adrenergic receptors has greatly
enhanced our understanding of the cellular and
biochemical actions of the catecholamine hormones.
In the broadest possible sense, these receptors serve
as excellent models for the study of the general
mechanisms of all G protein-coupled receptors.
Model systems using the cloned adrenergic receptors
will also undoubtedly prove critical to the resolution
of more specific problems, such as the controversy
regarding the relative importance of a-receptor sub-
types in genetic hypertension in rats.119-120 Elucida-
tion of the functional principles of these receptors
should lead to a better understanding of the mecha-
nisms involved in regulating hormone and drug
responsiveness as well as the molecular defects
underlying certain diseases.
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